Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With Diabetic Macular Edema

NCT06011798 is registered in ClinicalTrials.gov with Unity Biotechnology, Inc. as lead sponsor.

NCT NCT06011798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06011798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With Diabetic Macular Edema
Lead sponsor
Unity Biotechnology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 23, 2023
Completion date
April 8, 2025
Enrollment
52 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, diabetic macular edema, diabetic retinopathy, edema, eye diseases, macular edema, retinal degeneration, retinal disease, retinal diseases